The investigator hypothesize that the intervention group administered ViviGen® would, following surgery, experience:~Comparable bony fusion rates, evaluated via CT scan one year postoperatively~Comparable clinical outcome/ simplified COMI-score one year postoperatively~Comparable/ less inpatient length of stay (LOS)~Comparable/ less healthcare costs one year postoperatively~For patients included in the study, all follow-up is recorded, with regards to radiological and clinical outcome. Follow up will be evaluated after 14 days, 6 weeks, 6 and 12 months. Last follow up will be 1 year after surgery.
The aim of this study is to prospectively investigate the potential for bony fusion of ViviGen® bone graft substitute in comparison to rhBMP2 in standalone ALIF procedure L5/S1